Literature DB >> 11584982

Movement disorders associated with neuroleptic treatment.

W C Wirshing1.   

Abstract

Neuroleptic-induced movement disorders, or extrapyramidal side effects (EPS), can be classified into acute and tardive syndromes. Among the former are parkinsonism, dystonia, and akathisia. Conventional neuroleptics that have traditionally been used to treat psychiatric disorders are often associated with EPS. The newer atypical antipsychotics provide a more promising treatment strategy for psychiatric disorders and have a lower potential for producing EPS than conventional neuroleptics.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11584982

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN： 0160-6689            Impact factor:   4.384


  17 in total

Review 1.  Introduction to sertindole in clinical practice.

Authors:  Joseph Peuskens
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 2.  Are atypical antipsychotics safer than typical antipsychotics for treating behavioral and psychological symptoms of dementia?

Authors:  A Gurevich; V Guller; Y N Berner; S Tal
Journal:  J Nutr Health Aging       Date:  2012       Impact factor: 4.075

3.  Drug-induced parkinsonism.

Authors:  Frandy Susatia; Hubert H Fernandez
Journal:  Curr Treat Options Neurol       Date:  2009-05       Impact factor: 3.598

4.  Aripiprazole in the treatment of schizophrenia: a consensus report produced by schizophrenia experts in Italy.

Authors:  Giovan B Cassano; Andrea Fagiolini; Lorenzo Lattanzi; Palmiero Monteleone; Cinzia Niolu; Emilio Sacchetti; Alberto Siracusano; Antonio Vita
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

5.  Temporomandibular joint dislocation due to atypical antipsychotic-induced acute dystonia: a case report.

Authors:  M S Karthik; Nagarajan Prabhu
Journal:  Ther Adv Psychopharmacol       Date:  2014-12

6.  Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.

Authors:  Lakshmi N Yatham; Sidney H Kennedy; Sagar V Parikh; Ayal Schaffer; David J Bond; Benicio N Frey; Verinder Sharma; Benjamin I Goldstein; Soham Rej; Serge Beaulieu; Martin Alda; Glenda MacQueen; Roumen V Milev; Arun Ravindran; Claire O'Donovan; Diane McIntosh; Raymond W Lam; Gustavo Vazquez; Flavio Kapczinski; Roger S McIntyre; Jan Kozicky; Shigenobu Kanba; Beny Lafer; Trisha Suppes; Joseph R Calabrese; Eduard Vieta; Gin Malhi; Robert M Post; Michael Berk
Journal:  Bipolar Disord       Date:  2018-03-14       Impact factor: 6.744

Review 7.  First-episode schizophrenia: a focus on pharmacological treatment and safety considerations.

Authors:  Deanna L Kelly; Robert R Conley; William T Carpenter
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 8.  Extrapyramidal symptoms with atypical antipsychotics : incidence, prevention and management.

Authors:  Joseph M Pierre
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 9.  Striatal glutamatergic mechanisms and extrapyramidal movement disorders.

Authors:  Thomas N Chase; Francesco Bibbiani; Justin D Oh
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

Review 10.  Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review.

Authors:  Philip E Lee; Sudeep S Gill; Morris Freedman; Susan E Bronskill; Michael P Hillmer; Paula A Rochon
Journal:  BMJ       Date:  2004-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.